Back to search

Article

LY6G6D is Epigenetically Activated in Classical Colorectal Adenocarcinoma and Hyper-Methylated in Mucinous Subtypes Determining Resistance to FOLFOX Therapeutic Regimens.

2021-08-10

Abstract excerpt

<h4>Background: </h4> Colorectal cancer (CRC) represents a significant and ever-increasing societal threat and burden. Activation of Lymphocyte antigen 6G6D could induce anti-tumor specific immunity unique to CRC, but factors regulating its activation remain obscure. <h4>Methods: </h4>: Transcriptome, epigenome and proteomic data from TCGA and independent database were investigated using in silico approaches. Expr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4b19815b-cf56-50e4-bc21-beca37d9db5e
DOI
10.21203/rs.3.rs-783534/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
LY6G6D is Epigenetically Activated in Classical Colorectal Adenocarcinoma and Hyper-Methylated in Mucinous Subtypes Determining Resistance to FOLFOX Therapeutic Regimens.DOI 10.21203/rs.3.rs-783534/v1
Select a neighboring publication to make it the new centre.